Rosiglitazone promotes development of a novel adipocyte population from bone marrow–derived circulating progenitor cells
J. Clin. Invest. Joseph T. Crossno, et al. 116:3220 doi:10.1172/JCI28510 [Go to this article.]

Figure 1
ROSI increases circulating levels of BM-derived mesenchymal and hematopoietic progenitor cells. Flow cytometric analysis of PBMCs isolated from GFP⁺ BMT mice fed a control (Cntrl) or ROSI-impregnated (ROSI) diet for 3 (top and bottom rows) or 7 (middle row) weeks. Cells were stained with APC-conjugated anti-CD45 antibodies and either PE-labeled anti–Sca-1 (top and middle rows) or anti–c-kit (bottom row) antibodies and analyzed by flow cytometry as described in Methods. Gates were set and data corrected for results obtained with unstained cells or cells stained with APC- or PE-conjugated isotype-matched control antibodies. Representative scattergrams for each analysis are shown. Blue ovals indicate cells staining weakly for Sca-1 that were not detected in samples from control animals. The average percentage (from 3 independent experiments) of total GFP⁺ cells is indicated in the top left, top right, and bottom right quadrants.